Ampio Pharm

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. Show More...

  • Website https://www.ampiopharma.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.00 USD
  • Last Updated 23-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -0.49 -0.71 -0.34 -0.63 -0.76 -0.62 -0.36 -0.79 0.46 -0.14 -0.13
    Dividends USD
    Payout Ratio % *
    Shares Mil 16.0 26.0 34.0 38.0 50.0 52.0 54.0 65.0 91.0 131.0 143.0
    Book Value Per Share * USD -0.23 0.42 0.64 0.9 1.41 0.86 0.17 0.02 0.03 0.010
    Free Cash Flow Per Share * USD -0.16 -0.25 -0.29 -0.47 -0.82 -0.49 -0.38 -0.19 -0.15 -0.13
    Return on Assets % -181.59 -51.15 -77.61 -71.74 -53.05 -59.87 -358.98 231.63 -97.25 -128.99
    Financial Leverage (Average) 1.09 1.08 1.09 1.06 1.36 2.05 2.68 2.17 4.44
    Return on Equity % -267.02 -55.75 -84.38 -76.87 -62.09 -87.84 -233.41
    Return on Invested Capital % -267.0 -55.85 -84.42 -76.91 -56.68 -87.95 -186.49 -603.81
    Interest Coverage -411.04
    Current Ratio 0.16 8.83 10.91 10.69 13.93 5.3 2.53 2.18 5.78 1.93 0.77
    Quick Ratio 0.14 8.8 10.81 10.64 13.67 4.88 2.35 2.12 5.48 1.52 0.54
    Debt/Equity 0.13 0.19 0.57